Melanie D Everitt1, James D Wilkinson2, Ling Shi3, Jeffrey A Towbin4, Steven D Colan5, Paul F Kantor6, Charles E Canter7, Steven A Webber8, Daphne T Hsu9, Elfriede Pahl10, Linda J Addonizio11, Debra A Dodd8, John L Jefferies12, Joseph W Rossano13, Brian Feingold14, Stephanie M Ware15, Teresa M Lee11, Justin Godown8, Kathleen E Simpson7, Lynn A Sleeper5, Jason D Czachor2, Hiedy Razoky2, Ashley Hill2, Joslyn Westphal2, Kimberly M Molina16, Steven E Lipshultz2. 1. University of Colorado and Children's Hospital Colorado, Denver, CO. 2. Department of Pediatrics, Wayne State University School of Medicine and Children's Hospital of Michigan, Detroit, MI. 3. New England Research Institutes, Watertown, MA. 4. University of Tennessee Health Science Center, St. Jude Children's Research Hospital and Le Bonheur Children's Hospital, Memphis, TN. 5. Department of Cardiology, Boston Children's Hospital and Harvard Medical School, Boston, MA. 6. Department of Pediatrics, University of Alberta and Stollery Children's Hospital, Alberta, SK. 7. St. Louis Children's Hospital, Washington University, St. Louis, MO. 8. Department of Pediatrics, Vanderbilt University School of Medicine and Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN. 9. Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, NY. 10. Ann and Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL. 11. Departments of Pediatrics and Medicine, Columbia University Medical Center, New York, NY. 12. The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. 13. Children's Hospital of Philadelphia, Philadelphia, PA. 14. Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA. 15. Departments of Pediatrics and Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN. 16. Primary Children's Medical Center, Salt Lake City, UT.
Abstract
BACKGROUND: Cardiomyopathies are a rare cause of pediatric heart disease, but they are one of the leading causes of heart failure admissions, sudden death, and need for heart transplant in childhood. Reports from the Pediatric Cardiomyopathy Registry (PCMR) have shown that almost 40% of children presenting with symptomatic cardiomyopathy either die or undergo heart transplant within 2 years of presentation. Little is known regarding circulating biomarkers as predictors of outcome in pediatric cardiomyopathy. STUDY DESIGN: The Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers) study is a multi-center prospective study conducted by the PCMR investigators to identify serum biomarkers for predicting outcome in children with dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM). Patients less than 21 years of age with either DCM or HCM were eligible. Those with DCM were enrolled into cohorts based on time from cardiomyopathy diagnosis: categorized as new onset or chronic. Clinical endpoints included sudden death and progressive heart failure. RESULTS: There were 288 children diagnosed at a mean age of 7.2±6.3 years who enrolled in the PCM Biomarkers Study at a median time from diagnosis to enrollment of 1.9 years. There were 80 children enrolled in the new onset DCM cohort, defined as diagnosis at or 12 months prior to enrollment. The median age at diagnosis for the new onset DCM was 1.7 years and median time from diagnosis to enrollment was 0.1 years. There were 141 children enrolled with either chronic DCM or chronic HCM, defined as children ≥2 years from diagnosis to enrollment. Among children with chronic cardiomyopathy, median age at diagnosis was 3.4 years and median time from diagnosis to enrollment was 4.8 years. CONCLUSION: The PCM Biomarkers study is evaluating the predictive value of serum biomarkers to aid in the prognosis and management of children with DCM and HCM. The results will provide valuable information where data are lacking in children. CLINICAL TRIAL REGISTRATION NCT01873976: https://clinicaltrials.gov/ct2/show/NCT01873976?term=PCM+Biomarker&rank=1.
BACKGROUND: Cardiomyopathies are a rare cause of pediatric heart disease, but they are one of the leading causes of heart failure admissions, sudden death, and need for heart transplant in childhood. Reports from the Pediatric Cardiomyopathy Registry (PCMR) have shown that almost 40% of children presenting with symptomatic cardiomyopathy either die or undergo heart transplant within 2 years of presentation. Little is known regarding circulating biomarkers as predictors of outcome in pediatric cardiomyopathy. STUDY DESIGN: The Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers) study is a multi-center prospective study conducted by the PCMR investigators to identify serum biomarkers for predicting outcome in children with dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM). Patients less than 21 years of age with either DCM or HCM were eligible. Those with DCM were enrolled into cohorts based on time from cardiomyopathy diagnosis: categorized as new onset or chronic. Clinical endpoints included sudden death and progressive heart failure. RESULTS: There were 288 children diagnosed at a mean age of 7.2±6.3 years who enrolled in the PCM Biomarkers Study at a median time from diagnosis to enrollment of 1.9 years. There were 80 children enrolled in the new onset DCM cohort, defined as diagnosis at or 12 months prior to enrollment. The median age at diagnosis for the new onset DCM was 1.7 years and median time from diagnosis to enrollment was 0.1 years. There were 141 children enrolled with either chronic DCM or chronic HCM, defined as children ≥2 years from diagnosis to enrollment. Among children with chronic cardiomyopathy, median age at diagnosis was 3.4 years and median time from diagnosis to enrollment was 4.8 years. CONCLUSION: The PCM Biomarkers study is evaluating the predictive value of serum biomarkers to aid in the prognosis and management of children with DCM and HCM. The results will provide valuable information where data are lacking in children. CLINICAL TRIAL REGISTRATION NCT01873976: https://clinicaltrials.gov/ct2/show/NCT01873976?term=PCM+Biomarker&rank=1.
Authors: James D Wilkinson; David C Landy; Steven D Colan; Jeffrey A Towbin; Lynn A Sleeper; E John Orav; Gerald F Cox; Charles E Canter; Daphne T Hsu; Steven A Webber; Steven E Lipshultz Journal: Heart Fail Clin Date: 2010-10 Impact factor: 3.179
Authors: Steven E Lipshultz; E John Orav; James D Wilkinson; Jeffrey A Towbin; Jane E Messere; April M Lowe; Lynn A Sleeper; Gerald F Cox; Daphne T Hsu; Charles E Canter; Juanita A Hunter; Steven D Colan Journal: Lancet Date: 2013-09-03 Impact factor: 79.321
Authors: Jeffrey A Towbin; April M Lowe; Steven D Colan; Lynn A Sleeper; E John Orav; Sarah Clunie; Jane Messere; Gerald F Cox; Paul R Lurie; Daphne Hsu; Charles Canter; James D Wilkinson; Steven E Lipshultz Journal: JAMA Date: 2006-10-18 Impact factor: 56.272
Authors: Carol A Wittlieb-Weber; Kimberly Y Lin; Theoklis E Zaoutis; Matthew J O'Connor; Ken Gerald; Stephen M Paridon; Robert E Shaddy; Joseph W Rossano Journal: J Card Fail Date: 2014-10-24 Impact factor: 5.712
Authors: Stephen B Johnson; Glen Whitney; Matthew McAuliffe; Hailong Wang; Evan McCreedy; Leon Rozenblit; Clark C Evans Journal: J Am Med Inform Assoc Date: 2010 Nov-Dec Impact factor: 4.497
Authors: Steven D Colan; Steven E Lipshultz; April M Lowe; Lynn A Sleeper; Jane Messere; Gerald F Cox; Paul R Lurie; E John Orav; Jeffrey A Towbin Journal: Circulation Date: 2007-01-29 Impact factor: 29.690
Authors: Ellen O Weinberg; Masahisa Shimpo; Shelley Hurwitz; Shin-ichi Tominaga; Jean-Lucien Rouleau; Richard T Lee Journal: Circulation Date: 2003-02-11 Impact factor: 29.690
Authors: Peta M A Alexander; Piers E F Daubeney; Alan W Nugent; Katherine J Lee; Christian Turner; Steven D Colan; Terry Robertson; Andrew M Davis; James Ramsay; Robert Justo; Gary F Sholler; Ingrid King; Robert G Weintraub Journal: Circulation Date: 2013-09-13 Impact factor: 29.690
Authors: Kory J Lavine; Kathleen E Simpson; Melanie R F Gropler; Steven E Lipshultz; James D Wilkinson; Jeffrey A Towbin; Steven D Colan; Charles E Canter Journal: Pediatr Res Date: 2021-08-17 Impact factor: 3.953
Authors: V Pommier; H Abassi; K Lavastre; J Calderon; S Guillaumont; Y Dulac; F Auriol; C Ovaert; A Blondelon; S Hascoet; F Lecerf; C Jore; M Avesani; J-B Thambo; P Amedro Journal: Arch Pediatr Date: 2022-04-20 Impact factor: 1.820